Beauty N Botox Medspa
22186 Market Place Drive · New Caney, TX 77357
5.0(110 Google reviews · 43 in past year)
Accepts insurance
Listing updated Oct 2, 2026
WIN, MD Health and Aesthetics
WIN, MD Health and Aesthetics · 20306 U.S. 59 · New Caney, TX 77357
5.0· 49 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
WIN, MD Health and Aesthetics is a health and aesthetics practice in New Caney, Texas, whose listing shows weight-loss care, hormone services, IV therapy and aesthetics. On Google it has a 5.0-star rating across 49 reviews dating back to 2023, with 2 posted in the past year. Reviewers most often mention the staff and the providers' knowledge, and 6 reviews mention results. No website details were available, so it is worth asking what weight-management services are currently available.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 5.0
Google rating · 49 reviews
2
reviews in the past year (avg ★ 5.0)
2
reviews mention weight loss
Counts computed by RetaMaps from public Google reviews; most recent review 2026-08-22. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 49 Google reviews. Of the 49 reviews we analyzed, 49 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Friendly, helpful staff12 reviews
- Knowledgeable, professional providers9 reviews
- Weight-loss results6 reviews
- Feeling listened to6 reviews
Common complaints
No negative reviews among those we analyzed.
5★
49
4★
0
3★
0
2★
0
1★
0
Most recent Google reviews
Elizabeth H.★★★★★2026-08-22Ive come here for a couple years now. Could not sleep, had ache joints. I look and feel so much better. I wouldn't go anywhere else.
Amanda S.★★★★★2026-03-26Dr Nguyen and Lorena are extremely knowledgeable and very patient to answer any questions you have. I’m very PLEASED with my results! Thank y’all so much!
Wanda P.★★★★★2025-08-22Dr Win is the best!! I highly recommend his services. And Josephine, as well as the entire staff, is quite awesome.
Vicki R.★★★★★2025-08-21The Doctor is very informative. He listens to your concerns, and will guide you in the right direction. Will be returning!
joseph m.★★★★★2025-05-23no judgment whatsoever, & very knowledgeable
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Clinicians
- WIN, MD Health and Aesthetics
Nearby providers in New Caney
Accepts insurance
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs